735 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Roche's Rituxan Gets Priority Review for Blood Disorder http://www.zacks.com/stock/news/428757/roches-rituxan-gets-priority-review-for-blood-disorder?cid=CS-ZC-FT-428757 Jun 12, 2019 - Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer http://www.zacks.com/stock/news/428338/mercks-keytruda-wins-fda-nod-for-first-line-head-neck-cancer?cid=CS-ZC-FT-428338 Jun 12, 2019 - Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Roche Receives FTC Request for Further Data on Spark Buyout http://www.zacks.com/stock/news/427145/roche-receives-ftc-request-for-further-data-on-spark-buyout?cid=CS-ZC-FT-427145 Jun 10, 2019 - Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.
Lilly's Emgality Gets FDA Approval for Cluster Headache http://www.zacks.com/stock/news/425463/lillys-emgality-gets-fda-approval-for-cluster-headache?cid=CS-ZC-FT-425463 Jun 06, 2019 - Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.
Was ASCO Quieter for Big Drug/Biotech Stocks This Year? http://www.zacks.com/stock/news/425444/was-asco-quieter-for-big-drug-biotech-stocks-this-year?cid=CS-ZC-FT-425444 Jun 06, 2019 - The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Company News For Jun 4, 2019 http://www.zacks.com/stock/news/424463/company-news-for-jun-4-2019?cid=CS-ZC--424463 Jun 04, 2019 - Companies In The News Are: EE,CY,AMGN,MRK
Why Cancer-Fighting Stocks & ETFs Are Soaring http://www.zacks.com/stock/news/424108/why-cancer-fighting-stocks-etfs-are-soaring?cid=CS-ZC-FT-424108 Jun 03, 2019 - The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Amarin Rises on Priority Review for Vascepa Label Expansion http://www.zacks.com/stock/news/422062/amarin-rises-on-priority-review-for-vascepa-label-expansion?cid=CS-ZC-FT-422062 May 30, 2019 - Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.
Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion http://www.zacks.com/stock/news/421467/biotech-stock-roundup-amgns-nuevolution-buyout-celg-incy-drugs-label-expansion?cid=CS-ZC-FT-421467 May 29, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
3 Charts Every Amgen Investor Needs to See https://www.fool.com/investing/2019/05/26/3-charts-every-amgen-investor-needs-to-see.aspx?source=iedfolrf0000001 May 26, 2019 - These charts show there's a new Amgen emerging.

Pages: 1234567891011...74

<<<Page 6>